Galderma:
·Galderma achieved net sales of 3,009 M USD over the first nine months of 2023, up 8.9% year-on-year on a constant currency basis
·Continued pipeline progress with new milestones reached for nemolizumab and RelabotulinumtoxinA
·Galderma is on track to deliver at the upper end of its 2023 net sales guidance of 6-9% constant currency growth, and is in line with its profitability guidance of 200-300 bps core EBITDA margin expansion versus 2022
“We are very pleased with our st…